Home Newsfeeds Wolfe Research Upgrades Tricon Residential to Outperform

Wolfe Research Upgrades Tricon Residential to Outperform

Wolfe Research analyst Keegan Carl upgrades Tricon Residential (NYSE:TCN) from Peer Perform to Outperform.

byBenzinga Newsdesk

March 14, 2023

1 minute read

Wolfe Research analyst Keegan Carl upgrades Tricon Residential (NYSE:TCN) from Peer Perform to Outperform.

Morgan Stanley Maintains Overweight on HF Sinclair, Raises Price Target to $70

By Benzinga Newsdesk

November 8, 10:18 AM

Morgan Stanley analyst Connor Lynagh maintains HF Sinclair (NYSE:DINO) with a Overweight and raises the price target from $65 to $70.

DINO

Nurix Therapeutics Presents Clinical Data From Its Novel Bruton’s Tyrosine Kinase Degrader Programs, NX-5948 And NX-2127, At The 65th American Society Of Hematology Annual Meeting

By Benzinga Newsdesk

December 11, 1:02 PM

Positive preliminary efficacy data with a favorable safety profile support plans to develop NX-5948 broadly in chronic lymphocytic leukemia (CLL)Rapid durable complete responses in a heavily pretreated

NRIX

Analyst Ratings

Where Amphenol Stands With Analysts

By Benzinga Insights

July 1, 10:28 AM

Amphenol (NYSE:APH) has observed the following analyst ratings within the last quarter:

APH

Bitcoin Stock Canaan Up After Q1 Print, What’s Going On?

By Anusuya Lahiri

May 17, 9:39 AM

Canaan reported Q1 2024 revenue decline of 36.5%,but beat analyst estimate. Earnings per ADS loss of $(0.16) also beat estimate. Canaan holds $54.7M in cash, and its Bitcoin holdings reach 1,057. Q2 2024 revenue expected to be $70M, and Q3 expected to be $70M. CAN stock has plunged 55% in last 12 months.

CAN

Wolfe Research Upgrades Tricon Residential to Outperform

Related Posts

Morgan Stanley Maintains Overweight on HF Sinclair, Raises Price Target to $70

Nurix Therapeutics Presents Clinical Data From Its Novel Bruton’s Tyrosine Kinase Degrader Programs, NX-5948 And NX-2127, At The 65th American Society Of Hematology Annual Meeting

Where Amphenol Stands With Analysts

Bitcoin Stock Canaan Up After Q1 Print, What’s Going On?